Avrobio Names CFO as Interim CEO Following Departure of Founding CEO MacKay

Avrobio Names CFO as Interim CEO Following Departure of Founding CEO MacKay

Rare Daily Staff

Avrobio named its CFO Erik Ostrowski as interim CEO to replace its President and CEO Geoff MacKay, who is leaving to join an emerging early-stage company.

Ostrowski will continue in the CFO position. The Avrobio board has begun a search to identify a permanent CEO.

“As Avrobio prepares to transition to late-stage development in two exciting programs, Erik will provide steady leadership,” said Bruce Booth, chairman of the Avrobio board of directors.  A four-year veteran of the company, he has taken on increasing operational and leadership responsibilities over the past few years. We have great confidence in Erik’s ability to lead this transition as the Board conducts its search for a permanent CEO.”

Ostrowski brings more than 20 years of finance and biotech operating experience, including a focus on rare diseases and cell-based therapies. He is also currently a member of the board of Faron Pharmaceuticals. Prior to joining Avrobio, he was CFO at Summit Therapeutics, where he played a key role in executing the company’s NASDAQ initial public offering, completing multiple strategic transactions and building out the company’s U.S. operations.

Prior to joining Summit, Ostrowski served as vice president of finance at Organogenesis. He previously worked in investment banking, including as a director of healthcare investment banking with Leerink Partners. He began his career at PricewaterhouseCoopers and received a BS in accounting and economics from Babson College and an MBA from the University of Chicago Booth School of Business.